Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

  • 2 of 3

Targets for current and pipeline biologics

The discovery that asthma is a heterogeneous disease has paved the way for new, targeted biologic therapies. Omalizumab, which targets immunoglobulin E (lgE), was the first to be approved over a decade ago and at least six biologics that target interleukins have now reached human trials.